Evidence map›Paper›PMID 38439972›Full record

ArticleiScience2024

AI-enabled evaluation of genome-wide association relevance and polygenic risk score prediction in Alzheimer's disease.

Daniel E Platt, Aldo Guzmán-Sáenz, Aritra Bose, Subrata Saha, Filippo Utro, Laxmi Parida

Abstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel E PlattIBM T. J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Aldo Guzmán-SáenzIBM T. J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Aritra BoseIBM T. J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Subrata SahaPfizer, Pearl River, New York, NY, USA.
Filippo UtroIBM T. J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Laxmi ParidaIBM T. J. Watson Research Center, Yorktown Heights, New York, NY, USA.

Funding

Genome Center for Alzheimer's Disease (GCAD)U54AG052427 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2016 to 2025
$32.8M
NIA NIH HHS U54 AG052427
6 · The paper itself

Abstract

GWAS focuses on significance loosing false positives; machine learning probes sub-significant features relying on predictivity. Yet, these are far from orthogonal. We sought to explore how these inform each other in sub-genome-wide significant situations to define relevance for predictive features. We introduce the SVM-based RubricOE that selects heavily cross-validated feature sets, and LDpred2 PRS as a strong contrast to SVM, to explore significance and predictivity. Our Alzheimer's test case notoriously lacks strong genetic signals except for few very strong phenotype-SNP associations, which suits the problem we are exploring. We found that the most significant SNPs among ML and PRS-selected SNPs captured most of the predictivity, while weaker associations tend also to contribute weakly to predictivity. SNPs with weak associations tend not to contribute to predictivity, but deletion of these features does not injure it. Significance provides a ranking that helps identify weakly predictive features.

Indexed as

Association analysisBiocomputational methodHuman GeneticsMachine learningQuantitative genetics

Identifiers

PMID38439972
PMCPMC10910245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.